Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 184 results

Notice of Special Interest (NOSI): Ruth L. Kirschstein National Research Service Award (NRSA) Fellowship Awards to Support Training in Research Related to Down Syndrome as Part of the INCLUDE Project

Notice of Special Interest
Friday, December 6, 2019
Saturday, January 8, 2022
NOT-OD-20-020

Funding Opportunity Purpose

Notice Special Interest NOSI): Ruth L. Kirschstein National Research Service Award NRSA) Fellowship Awards Support Training Research Related Down Syndrome Part the INCLUDE Project Notice Number: NOT-OD-20-020 Key Dates Release Date: December 6, 2019 First Available Due Date: April 08, 2020 Expiration Date: January 08, 2022 Related Announcements NOT-OD-20-024 NOT-OD-20-023 NOT-OD-20-012 Notice Intent Publish Funding Opportunity Announcements Fiscal Year 2020 the INCLUDE INvestigation Co-occurring conditions across Lifespan Understand Down syndromE) Project PA-19-191 Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-192 Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-195 Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Parent F31) PA-19-196 Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Promote Diversity Health-Related Research Parent F31 - Diversity) PA-19-188 Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship Parent F32) RFA-OD-20-004 RFA-OD-20-003 RFA-OD-20-005 RFA-OD-20-006 RFA-OD-20-007NOT-OD-20-025 NOT-OD-20-022 Issued Office The Director, National Institutes Health OD) National Cancer Institute NCI) National Heart, Lung, Blood Institute NHLBI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases (NIAMS) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) Purpose Background INvestigation Co-occurring conditions across Lifespan Understand Down syndromE INCLUDE) Project developed response Fiscal Year 2018 2019 Omnibus Appropriations Reports, encouraged NIH expand current efforts Down syndrome DS) common co-occurring conditions also seen the general population while increasing pipeline DS investigators. Information projects were funded in 2018 2019, well the INCLUDE Project Research Plan?, available the INCLUDE Project website. Individuals DS face significant changing health challenges have often excluded participation research could improve health outcomes quality life. population understudied even though DS the most common genetic cause intellectual developmental disabilities IDD) and, the past 25 years, average lifespan doubled 30 60 years. addition intellectual disability, DS associated an increased prevalence autism epilepsy. 75% individuals DS experience cognitive decline a syndrome resembles Alzheimer’s disease, with onset decade two earlier typical Alzheimer’s disease. Individuals DS also high rates hearing loss, eye abnormalities, congenital heart defects, sleep apnea, pulmonary hypertension, gastrointestinal malformations, thyroid disease, leukemia, other autoimmune immune dysregulation disorders including celiac disease. However, people DS infrequently develop solid tumors such breast prostate cancer. Despite multiple risk factors coronary artery disease high rates obesity, sleep apnea, type 1 diabetes, people DS rarely develop atherosclerosis have myocardial infarctions. Understanding unique combination risk resiliencies inform medical advances individuals DS for individuals do have DS who share co-occurring conditions. Research Objectives Notice Special Interest NOSI) announces NIH support the professional development trainees aiming establish career DS-related research. providing scientists training, resources, mentorship, NIH intends foster pipeline investigators DS other intellectual disabilities will lead future research improve understanding the biology DS support development new treatments health conditions experienced those DS. Investigators early their careers e.g., predoctoral candidates) well those advanced degrees e.g., PhD, MD) benefit mentorship established investigators professionals the DS research community basic science fields well clinical translational arenas. NIH issuing NOSI expand community investigators conducting research related DS encouraging scientists physicians early their research careers develop research projects related co-occurring conditions associated DS. Sharing resources effective communication outputs the broader communities a high priority the INCLUDE Project. Applicants responding this NOSI strongly encouraged describe plans rapid sharing data results well innovative data analytics approaches Goal 3, NIH Strategic Plan Data Science). list of Funding Priorities Institute Center for project available the INCLUDE website. Applications response this NOSI should aligned the overall INCLUDE Project Research Plan, consists three components: Component 1: Targeted, high risk-high reward, basic science studies areas highly relevant Down syndrome Component 2: Cohort Study connect existing resources expand inclusion individuals Down syndrome Component 3: Inclusive clinical trials research co-occurring conditions individuals Down syndrome Projects propose recruit subjects DS encouraged promote enrollment research subjects the DS patient registry supported NIH, DS-Connect®. other data biospecimens human genetic non-genetic studies, awardees encouraged use biorepositories designated INCLUDE staff meet requirements broad sharing. NIH resource describing Common Data Elements may helpful during planning phases a project considering ways optimize data collection order facilitate broad data sharing. Application Submission Information Notice applies due dates or after April 8, 2020 expires January 8, 2022. Applications response this NOSI must submitted using of following target funding opportunity Announcements FOAs) their reissued equivalents. Although all NIH components indicated above listed Participating Organizations all FOAs listed below, applications this special topic be accepted. PA-19-191 Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-192 Ruth L. Kirschstein National Research Service Award NRSA) Individual Fellowship Students Institutions Without NIH-Funded Institutional Predoctoral Dual-Degree Training Programs Parent F30) PA-19-195 Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Parent F31) PA-19-196 Ruth L. Kirschstein National Research Service Award NRSA) Individual Predoctoral Fellowship Promote Diversity Health-Related Research Parent F31 - Diversity) PA-19-188 Ruth L. Kirschstein National Research Service Award NRSA) Individual Postdoctoral Fellowship Parent F32) instructions the SF424 R&R) Application Guide and listed funding opportunity announcements must followed, the following addition: funding consideration, applicants must include NOT-OD-20-020 in Agency Routing Identifier field box 4b) the SF424 R&R form. Applications without information box 4b not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative.   Inquiries Please direct inquiries the contacts Section VII the listed funding opportunity announcements the following additions/substitutions: list of contacts for participating NIH Institute Center available the INCLUDE website.    

Notice of Special Interest: Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp Clinical Trial Optional)

Notice of Special Interest
Thursday, December 5, 2019
Tuesday, January 26, 2021
333
NOT-OD-20-032

Funding Opportunity Purpose

Notice Special Interest: Administrative Supplements Research Sexual Gender Minority SGM) Populations Admin Supp Clinical Trial Optional) Notice Number: NOT-OD-20-032 Key Dates Release Date: December 6, 2019 First Available Due Date: January 31, 2020 Expiration Date: January 26, 2021 nbsp; Related Announcements PA-18-591 Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) Issued National Institutes Health NIH) Sexual amp; Gender Minority Research Office SGMRO) National Center Complementary Integrative Health NCCIH) National Cancer Institute NCI) National Human Genome Research Institute NHGRI) National Heart, Lung, Blood Institute NHLBI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Allergy Infectious Diseases NIAID) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Drug Abuse NIDA) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Diabetes Digestive Kidney Diseases NIDDK) National Institute Mental Health NIMH) National Institute Minority Health Health Disparities NIMHD) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) Additionally, following NIH Offices co-fund applications assigned these Institutes Centers: Office Behavioral Social Sciences Research OBSSR) Office Research Women’s Health ORWH) Purpose mission the NIH to seek fundamental knowledge the nature behavior living systems the application that knowledge enhance health, lengthen life, reduce illness disability. NIH committed supporting research will increase scientific understanding the health wellbeing various population subpopulation groups that help establish effectiveness evidence-based health interventions services individuals within groups. NIH places high priority research populations appear have distinctive health risk profiles who also received insufficient attention investigators. this end, Notice Special Interest NOSI) announces availability administrative supplements provide funding the expansion existing research projects incorporate sexual gender minority SGM) populations, include, are limited to, those populations described Notice NOT-OD-19-139. Basic, social, behavioral, clinical, translational, health services research relevant the missions the sponsoring NIH Institutes Centers ICs) be proposed response this solicitation. Potential applicants also encouraged review the FY 2017 Portfolio Analysis of NIH-funded SGM research identify potential research gaps may relevant this NOSI. Background Although collective knowledge base SGM health grown substantially since release the 2011 Institute Medicine the National Academy Medicine) report on health lesbian, gay, bisexual, transgender people, continually growing body evidence indicates SGM individuals still suffer disproportionately numerous conditions, diseases, health issues compared the general population. October 2016, the National Institute Minority Health Health Disparities, collaboration the Agency Healthcare Research Quality, announced that SGMs been officially designated health disparity population. designation facilitated creation tailored research projects, programs, activities, funding opportunities tackle unique health-related issues encountered SGM individuals. addition, ascertainment SGM status ongoing planned population studies been enhanced. However, SGM-specific health disparities persist today, there still urgent need novel strategies understand, measure, address, prevent them. of August 28, 2019, NIH definition sexual gender minorities" includes, is limited to, individuals identify lesbian, gay, bisexual, asexual, transgender, two-spirit, queer, and/or intersex. Individuals same-sex gender attractions behaviors those a difference sex development also included. populations also encompass those do self-identify one these terms whose sexual orientation, gender identity expression, reproductive development characterized non-binary constructs sexual orientation, gender, and/or sex. Applicants this administrative supplement propose study relevant SGM subpopulations explicitly identified this definition and/or adopt classification frameworks terminologies appropriate. Specific Areas Research Interest NOSI calls research will enrich scientific understanding how sexual orientation, gender identity, and/or being born disorders/differences sex development intersex conditions relate health outcomes, health risks, health behaviors, perceptions expectations health, access health-related services associated barriers. Appropriate topics studies these supplements include, are limited to, those listed below: Addition SGM participants an ongoing study either not originally include or not enrolled enough SGM participants make meaningful comparisons between groups; proposed studies must sufficiently powered allow meaningful comparisons Expansion an ongoing study focused one SGM group add another; proposed studies must sufficiently powered allow meaningful comparisons Expansion surveys questionnaires add items related sexual attraction, sexual behavior, sexual identity, gender identity, gender expression, and/or non-binary sex relevant appropriate Assessment reliability and/or validity measures relevant sexual attraction, sexual behavior, sexual identity, gender identity, gender expression, and/or non-binary sex Methodological strategic innovations improve recruitment retention SGM individuals any research activity Ethical, legal, social science research the implications data collection and/or research findings SGM populations Scope Support Administrative supplements be used meet increased costs are within scope the approved parent award, that unforeseen the new renewal application grant progress report non-competing continuation support submitted. Applicants this NOSI should propose research that, successful, contribute a greater understanding the health wellbeing SGM communities. Clinical trials cannot proposed be added grants do include clinical trial since would constitute change scope. IC-Specific Considerations applications submitted response this NOSI should fall within mission the IC the awarded parent grant. Applicants strongly encouraged discuss proposed supplement project the IC Program Officer the funded parent award prior submission a supplement application order ensure the proposed activity aligns the scientific priorities the IC is within scope the parent award. Scientific inquiries also addressed the contacts listed the Inquiries section below. Information   Recently issued trans-NIH policy notices may affect application submission. full list policy notices published NIH provided the NIH Guide Grants Contracts. awards subject the terms conditions, cost principles, other considerations described the NIH Grants Policy Statement. Authority Regulations Awards made under authorization Sections 301 405 the Public Health Service Act amended 42 USC 241 284) under Federal Regulations 42 CFR Part 52 45 CFR Part 75. Application Submission Information Applications this initiative must submitted using following opportunity its subsequent reissued equivalent: PA-18-591 - Administrative Supplements Existing NIH Grants Cooperative Agreements Parent Admin Supp Clinical Trial Optional) instructions the SF424 R&R) Application Guide and PA-18-591 must followed the following additions: Application Due Dates – January 31, 2020 FY 2020, January 25, 2021 FY 2021, 5:00 PM local time applicant organization. expiration date January 26, 2021. project budget periods must within currently approved project period the existing parent award. funding consideration, applicants must include ldquo;NOT-OD-20-032” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Requests be one year support only. project budget cannot exceed 100,000 total costs. Research Strategy section the application limited 6 pages. process Streamlined Submissions using eRA Commons cannot used this initiative. Applicants strongly encouraged notify Program Officer the IC supporting parent award a request been submitted response this NOSI order facilitate efficient processing the application. Applications do comply these instructions be delayed not accepted review. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries the Program Officer associated the parent award and/or designated contact the IC supporting parent award listed below: Scientific/Research Contact(s) Della White, PhD National Center Complementary Integrative Health NCCIH) Telephone: 301-827-6358 whitede@mail.nih.gov Liz Perruccio, PhD National Cancer Institute NCI) Telephone: 240-276-6178 Email: perruccioem@mail.nih.gov Tina Gatlin, PhD National Human Genome Research Institute NHGRI) Telephone: 301-?480-2280 Email: gatlincl@mail.nih.gov Brad Newsome, PhD National Heart, Lung, Blood Institute NHLBI) Telephone: 301-827-8170 Email: brad.newsome@nih.gov Melissa Gerald, PhD National Institute Aging NIA) Telephone: 301-?496-3136 Email: melissa.gerald@nih.gov Robert Freeman, PhD National Institute Alcohol Abuse Alcoholism NIAAA) Telephone: 301-443-8820 Email: rfreeman@mail.nih.gov Philip Renzullo, PhD, MPH National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3041 Email: prenzullo@mail.nih.gov Heiyoung Park, PhD National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5032 Email: parkh1@mail.nih.gov Jeffrey Schulden, MD National Institute Drug Abuse NIDA) Telephone: 301-402-1526 Email: schuldenj@mail.nih.gov Alberto Rivera-Rentas, PhD National Institute Deafness Other Communication Disorders NIDCD) Telephone: 301-496-1804 Email: riverara@mail.nih.gov Elise Rice, PhD National Institute Dental Craniofacial Research NIDCR) Telephone: 301-594-4814 Email: elise.rice@nih.gov Tamara Bavendam, MD, MS National Institute Diabetes Digestive Kidney Diseases NIDDK) Telephone: 301-594-4733 Email: bavendamtg@mail.nih.gov Tamara Lewis Johnson, MPH, MBA National Institute Mental Health NIMH) Telephone: 301-594-7963 Email: tl247e@nih.gov Jennifer Alvidrez, PhD National Institute Minority Health Health Disparities NIMHD) Telephone: 301-594-9567 Email: alvidrezjl@mail.nih.gov Richard Benson, MD, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9135 Email: richard.benson@nih.gov Rebecca Henry, PhD, BSN, RN National Institute Nursing Research NINR) Telephone: 301-594-5976 Email: rebecca.henry@nih.gov Rajasri Roy, PhD, MPH Office Research Women’s Health ORWH) Telephone: 301-451-0993 Email: royr2@mail.nih.gov nbsp;

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)

RFA
Thursday, November 14, 2019
Workforce Diversity
Saturday, November 12, 2022
K99/R00
RFA-NS-19-043

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA.

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)

RFA
Thursday, November 14, 2019
Workforce Diversity
Saturday, November 12, 2022
K99/R00
RFA-NS-19-044

Funding Opportunity Purpose

The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.

Notice of Special Interest: Advancing Research for Tickborne Diseases (TBDs)

Notice of Special Interest
Tuesday, November 12, 2019
Sunday, January 8, 2023
NOT-AI-20-005

Funding Opportunity Purpose

Notice Special Interest: Advancing Research Tickborne Diseases TBDs) Notice Number: NOT-AI-20-005 Key Dates Release Date: November 12, 2019 First Available Due Date: January 05, 2020 Expiration Date: January 08, 2023 Related Announcements PA-19-055 NIH Research Project Grant Parent R01 Clinical Trial Required) PA-19-056 NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-270 PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed) PA-19-272 PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PAR-19-134 Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) Issued National Institute Allergy Infectious Diseases NIAID ) National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) National Institute Mental Health NIMH ) National Institute Neurological Disorders Stroke NINDS) National Center Complementary Integrative Health NCCIH ) Purpose purpose this Notice to announce the National Institute Allergy Infectious Diseases NIAID), National Institute Arthritis Musculoskeletal Skin Diseases NIAMS), National Institute Mental Health NIMH), National Institute Neurological Disorders Stroke NINDS), the National Center Complementary Integrative Health NCCIH) encourage new applications advance research activities relevant the five strategic priorities identified the recently released NIH Strategic Plan Tickborne Disease Research: Improve fundamental knowledge TBDs to understand host, vector, pathogen factors drive TBD pathogenesis transmission. Elucidate host immune mechanisms response and exploited TBD pathogens. Advance research improve diagnosis TBDs using both host- pathogen-targeted approaches, including research rapid diagnostics multiplex platform approaches detect multiple tickborne pathogens. Accelerate research improve TBD prevention by supporting science design, develop, evaluate vaccines, vector control strategies, other prevention approaches. Promote research improve treatment all forms TBDs, including studies develop effective therapies treat symptoms persist after TBD treatment, therapies non-infectious TBDs, new antimicrobials. Support tools resources advance research understanding, preventing, diagnosing, treating TBDs, including repositories, genomic resources, animal models, preclinical services aid development assessment diagnostic, vaccine, therapeutic candidates. NIAID: NIAID support research the biology tickborne pathogens, vectors, animal reservoirs, human hosts, the interactions among elements they help understand underlying causes human disease. NIAID interested applications the basic science behind tickborne infections in applications seeking develop new approaches prevent, diagnose, treat those infections. NIAID also support research non-infectious TBDs, particularly alpha-gal syndrome. focus research this syndrome to understand pathogenesis develop improved diagnostics therapeutic approaches. NIAMS : NIAMS interested supporting research studies human immunity its role the initiation propagation Lyme arthritis. of systems biology approaches identify critical cellular molecular pathways involved pathogenesis encouraged. interests include studies the joint tissue remodeling pathways the cross-talk a wide range hematopoietic other cell types Lyme arthritis. Please note, NIAMS only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. NIMH: As lead federal agency research mental disorders, NIMH interested the following areas: Basic mechanistic neuroscience studies persistent effects Lyme disease brain signaling, circuits, proximal effects functional processes such cognition are impaired mental illnesses. Research illuminate mechanisms which tick-borne diseases lead specific psychiatric complications. Research understand neurobiological basis the impact tick-borne diseases specific domains functions relevant mental health, informed the Research Domain Criteria RDoC) approach. Research decrease burden acute chronic psychiatric complications Lyme disease other tick-borne diseases. Please note, NIMH only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. NINDS : NINDS interested supporting research the basic biology mechanisms the neurological consequences tick-borne diseases. includes developing animal cell models will facilitate studying nervous system pathogenesis these diseases developing new approaches diagnose treat neurological complications. Please note, NINDS only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. NCCIH: NCCIH support research the mechanisms which complementary integrative health approaches improve tick-borne disease TBD) treatment and/or post-TBD symptom care. Complementary integrative approaches include mind/brain-focused practices i.e., meditation, hypnosis), body-based approaches i.e., acupuncture, massage, spinal manipulation), meditative exercise i.e., yoga, tai chi, qi gong), natural products i.e., botanicals, dietary supplements, probiotics), isolation in combination conventional medical treatments. NCCIH not accept clinical trial measures efficacy effectiveness any intervention through NOSI. NCCIH only accepts mechanistic studies meet NIH's definition a clinical trial PA-19-055. Application Submission Information notice applies due dates or after January 5, 2020 subsequent receipt dates through January 8, 2023. Submit applications this initiative using of following funding opportunity announcements FOAs) any reissues these announcement through expiration date this notice. PA-19-055 NIH Research Project Grant Parent R01 Clinical Trial Required) PA-19-056 NIH Research Project Grant Parent R01 Clinical Trial Allowed) PA-19-270 PHS 2019-02 Omnibus Solicitation the NIH Small Business Technology Transfer Grant Applications Parent STTR R41/R42] Clinical Trial Allowed) PA-19-272 PHS 2019-02 Omnibus Solicitation the NIH, CDC, FDA Small Business Innovation Research Grant Applications Parent SBIR R43/R44] Clinical Trial Allowed) PAR-19-134 Research Enhancement Award Program REAP) Health Professional Schools Graduate Schools R15 Clinical Trial Allowed) instructions the SF424 R&R) Application Guide and funding opportunity announcement used submission must followed, the following additions: funding consideration, applicants must include ldquo;NOT-AI-20-005” without quotation marks) the Agency Routing Identifier field box 4B) the SF424 R&R form. Applications without information box 4B not considered this initiative. Applications nonresponsive terms this NOSI be be considered the NOSI initiative. Inquiries Please direct inquiries to: Samuel Perdue, Ph.D. National Institute Allergy Infectious Diseases NIAID) Telephone: 240-627-3341 E-mail: sperdue@nih.gov Yisong Wang, PhD. National Center Complementary Integrative Health NCCIH) Telephone: 301-480-9483 E-mail: yisong.wang@nih.gov Su-Yau Mao, Ph.D. National Institute Arthritis Musculoskeletal Skin Diseases NIAMS) Telephone: 301-594-5032 Email: maos2@mail.nih.gov Sarah H. Lisanby, M.D.. National Institute Mental Health NIMH) Telephone: 301-451-3029 Email: lisanbysh@mail.nih.gov Wong, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1431 Email: wongm@ninds.nih.gov

Support of Competitive Research (SCORE) Pilot Project Award (SC2 - Clinical Trial Not Allowed)

PAR
Thursday, October 24, 2019
Workforce Diversity
Thursday, September 8, 2022
PAR-20-040

Funding Opportunity Purpose

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

Support of Competitive Research (SCORE) Research Advancement Award (SC1 - Clinical Trial Not Allowed)

PAR
Thursday, October 24, 2019
Workforce Diversity
Thursday, September 8, 2022
PAR-20-039

Funding Opportunity Purpose

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

Support of Competitive Research (SCORE) Research Continuance Award (SC3 - Clinical Trial Not Allowed)

PAR
Thursday, October 24, 2019
Workforce Diversity
Thursday, September 8, 2022
PAR-20-041

Funding Opportunity Purpose

The SCORE Program is a developmental program designed to increase the research competitiveness of faculty and the research base at institutions with an explicitly stated historical mission and/or a demonstrated track record within the previous 10 years of training and graduating students from backgrounds underrepresented in biomedical research. Eligible institutions must award science degrees to undergraduate (B.S. or B.A.) and/or graduate students (M.S. or Ph.D.) and have received less than 6 million dollars per year of NIH R01 support (total costs) in each of the last 2 fiscal years.

NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)

PAR
Friday, October 18, 2019
Tuesday, January 10, 2023
F32
PAR-20-021

Funding Opportunity Purpose

(Reissue of PAR-16-458) The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in postdoctoral position. Based on the early timeframe of eligibility, and the discouragement of inclusion of preliminary data, this NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Applications are expected to incorporate strong training in quantitative reasoning and the quantitative principles of experimental design and analysis. Support by this program is limited to the first 3 years of a candidate's activity in a specific laboratory or research environment, so as to further encourage early fellowship application and timely completion of mentored training of the postdoctoral candidate in a single environment.

HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)

RFA
Friday, October 4, 2019
Friday, September 9, 2022
R41/R42
RFA-NS-20-009

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies.

Pages